This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 (EVIDENS)

This study has been completed.
Information provided by (Responsible Party):
Henrik Wagner, Karolinska Institutet Identifier:
First received: December 20, 2011
Last updated: September 9, 2014
Last verified: September 2014
The purpose of this study is to evaluate if treatment with vitamin D increase beta cell function and insulin sensitivity in subjects with pre-diabetes or newly diagnosed diabetes mellitus type 2.

Condition Intervention Phase
Diabetes Mellitus, Type 2 Glucose Intolerance Vitamin D Deficiency Drug: Vitamin D3 Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 - EVIDENS

Resource links provided by NLM:

Further study details as provided by Henrik Wagner, Karolinska Institutet:

Primary Outcome Measures:
  • Beta cell function [ Time Frame: 8 weeks ]
    Assessed by hyperglycemic clamp investigation

Secondary Outcome Measures:
  • Insulin sensitivity [ Time Frame: 8 weeks ]
    Assessed by hyperglycemic clamp investigation

  • Glucose tolerance [ Time Frame: 8 weeks ]
    Assessed by OGTT

  • Hypercalcemia [ Time Frame: 8 weeks ]

Enrollment: 44
Study Start Date: January 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vitamin D3 Drug: Vitamin D3
Oral drops 30000 IU weekly
Other Name: Vigantol oil
Placebo Comparator: Placebo Drug: Placebo
Matching placebo


Ages Eligible for Study:   45 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meeting criteria for IFG, IGT, IFG+IGT or diabetes mellitus at OGTT.
  • BMI ≤ 32 kg/m2.
  • HbA1c ≤ 7.0 % (MonoS) or ≤ 63 mmol/mol (IFCC).
  • Fasting plasma glucose < 9 mmol/l
  • S-25-OH-vitamin D3 < 75 nmol/l.

Exclusion Criteria:

  • Treatment with any vitamin D preparation.
  • Regular sun-bathing in solarium.
  • Hypercalcemia at screening, defined as free s-calcium > 1.35 mmol/l.
  • Hyperphosphatemia at screening, defined as s-phosphate > 1.5 mmol/l.
  • Sarcoidosis or other granulomatous disease.
  • Treatment with phenytoin, barbiturates, rifampicin, isoniazid, cardiac glycosides, orlistat or colestyramin.
  • Impaired hepatic function.
  • Impaired renal function
  • Cardiac disease defined as:

    • Unstable angina pectoris
    • Myocardial infarction within the last 6 months
    • Congestive heart failure NYHA class III and IV
  • Cerebral stroke within the last 6 months.
  • Anti-diabetic medication of any kind.
  • Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01497132

Dpt of Endocrinology, Karolinska University Hospital
Stockholm, Sweden, 17176
Sponsors and Collaborators
Karolinska Institutet
Principal Investigator: Henrik Wagner, M.D Karolinska Institutet
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Henrik Wagner, Principal Investigator, Karolinska Institutet Identifier: NCT01497132     History of Changes
Other Study ID Numbers: DvitamininDM2_v1_110815
2010-024487-18 ( EudraCT Number )
Study First Received: December 20, 2011
Last Updated: September 9, 2014

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Insulin Resistance
Vitamin D Deficiency
Prediabetic State
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Deficiency Diseases
Nutrition Disorders
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Hypoglycemic Agents processed this record on September 19, 2017